Mr. Chris Jackson reports

DOSEOLOGY APPOINTS LARRY LATOWSKY AS EXECUTIVE CHAIRMAN OF THE BOARD OF DIRECTORS

Doseology Sciences Inc. has appointed Larry Latowsky as a director and the executive chairman of its board of directors, effective Feb. 18, 2026.

Doseology is focused on developing precision-controlled oral delivery systems within the emerging oral stimulant category. Guided by harm-reduction-oriented design principles, the company aims to improve predictability and control in innovative consumer stimulant formats. As an early-stage platform company, Doseology is intentionally building its foundation -- covering governance, intellectual property and repeatable delivery systems -- prior to scaling commercialization and broader growth initiatives.

The appointment of Mr. Latowsky reflects the company's confidence in both the timing of the category and the capability of its team to execute. His extensive experience operating at the intersection of public markets, institutional-scale enterprises and regulated consumer health businesses is expected to strengthen Doseology's governance, capital markets strategy and overall strategic decision making as it advances from early innovation toward broader commercialization.

In connection with his appointment, the company has granted Mr. Latowsky 4,000 restricted share units (RSUs) and 6,000 performance share units (PSUs). The RSUs will vest monthly over a period of 36 months. The PSUs shall vest upon achievement of certain performance milestones.

Doseology's strategy is informed by the maturity of regulated oral stimulant and nicotine-adjacent formats in European markets, where modern oral delivery systems are well established, and by the growing acceptance of better-for-you oral alternatives in North America. In this environment, disciplined execution, thoughtful product architecture and credible leadership are key differentiators as the category evolves.

North America presents a large addressable market for oral stimulant and nicotine-adjacent formats, characterized currently by a limited number of scaled participants and a fragmented offerings landscape. Doseology believes this structure creates a compelling opportunity for teams capable of building durable platforms through governance, strategic execution and network-driven partnerships -- rather than rapid, undisciplined expansion.

Mr. Latowsky, a graduate of the University of Toronto Rotman School of Management and the Institute of Corporate Directors of Canada, brings expertise in corporate governance. He has served on numerous profit and non-profit boards, both public and private, demonstrating a broad commitment to governance excellence. His background includes working alongside institutional investors, public-market stakeholders, and strategic acquirers -- experience directly relevant as Doseology continues to build credibility with shareholders and the broader investment community.

Most notably, Mr. Latowsky previously served as president and chief executive officer of Katz Group Canada, the parent organization of Rexall -- Pharma Plus, I.D.A. and Guardian Drugs stores, one of Canada's most established pharmacy chains. During his tenure, Katz Group Canada operated a nationwide retail pharmacy network of 1,500 locations. The value and operational foundation he established as chief executive officer played a significant role in enhancing the company's attractiveness and strategic positioning, ultimately facilitating its acquisition by McKesson Corp. in a deal valued at approximately $3-billion. This experience provided him with direct exposure to institutional-scale transactions, public-company counterparties and governance standards associated with large-cap acquirers.

In addition, Mr. Latowsky served as chairman of the board for Well.ca, one of Canada's leading health and wellness e-commerce platforms. His involvement offers valuable insight into scaling direct-to-consumer health platforms and navigating ownership transitions within broadly governed environments.

He also held executive roles as president and CEO of Drug Trading Company Ltd., overseeing pharmacy banners including I.D.A. and Guardian Drugs, and served as CEO of ProPharm Technology and DC Labs -- an integrated pharmaceutical manufacturing and packaging platform. His operational experience within regulated manufacturing and distribution environments is expected to support Doseology's focus on disciplined execution, compliance and scalable production as it advances its oral delivery systems.

"Larry's appointment strengthens Doseology at a critical early stage," said Chris Jackson, chief executive officer of Doseology Sciences. "His experience building and governing scaled platforms, combined with his confidence in our strategy and team, reinforces our belief that Doseology is well positioned to execute thoughtfully and create meaningful long-term value for shareholders."

"What attracted me to Doseology is the clarity of its strategy and the quality of its team," said Mr. Latowsky. "The company is approaching an emerging category with discipline, purpose and a focus on execution. I am confident that, together, leveraging our networks and collective experience, we can build a durable platform and unlock significant long-term value."

About Doseology Sciences Inc.

Doseology Sciences is an early-stage platform company dedicated to developing precision-controlled, science-backed oral delivery systems within the oral stimulant category. Guided by harm-reduction-oriented design principles, the company emphasizes intellectual property development and disciplined execution to create scalable solutions aimed at sustainable, long-term value creation.

We seek Safe Harbor.